BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen JN, He D, Tang F, Shao CK. Epstein-Barr virus-associated gastric carcinoma: a newly defined entity. J Clin Gastroenterol. 2012;46:262-271. [PMID: 22392024 DOI: 10.1097/mcg.0b013e318249c4b8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 27] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Zhang YW, Zhao XX, Tan C, Zhang ZG, Jiang Y, Chen JN, Wei HB, Xue L, Li HG, Du H, Shao CK. Epstein-Barr virus latent membrane protein 2A suppresses the expression of HER2 via a pathway involving TWIST and YB-1 in Epstein-Barr virus-associated gastric carcinomas. Oncotarget 2015;6:207-20. [PMID: 25402957 DOI: 10.18632/oncotarget.2702] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
2 Wang A, Zhang W, Jin M, Zhang J, Li S, Tong F, Zhou Y. Differential expression of EBV proteins LMP1 and BHFR1 in EBV‑associated gastric and nasopharyngeal cancer tissues. Mol Med Rep 2016;13:4151-8. [PMID: 27052804 DOI: 10.3892/mmr.2016.5087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
3 Aituov B, Duisembekova A, Bulenova A, Alibek K. Pathogen-driven gastrointestinal cancers: Time for a change in treatment paradigm? Infect Agent Cancer. 2012;7:18. [PMID: 22873119 DOI: 10.1186/1750-9378-7-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
4 Elgui de Oliveira D, Müller-Coan BG, Pagano JS. Viral Carcinogenesis Beyond Malignant Transformation: EBV in the Progression of Human Cancers. Trends Microbiol. 2016;24:649-664. [PMID: 27068530 DOI: 10.1016/j.tim.2016.03.008] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 9.3] [Reference Citation Analysis]
5 Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R, Battaglin F, Soni S, McSkane M, Zhang W, Lenz HJ. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 2018;66:15-22. [PMID: 29631196 DOI: 10.1016/j.ctrv.2018.03.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 12.5] [Reference Citation Analysis]
6 Yang F, He K, Huang L, Zhang L, Liu A, Zhang J. Casticin inhibits the activity of transcription factor Sp1 and the methylation of RECK in MGC803 gastric cancer cells. Exp Ther Med 2017;13:745-50. [PMID: 28352361 DOI: 10.3892/etm.2016.4003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
7 Lee SH, Choi SJ, Choi W, Cho S, Cho M, Kim DS, Kang BW, Kim JG, Lee YM, Cho H, Kang H. Cisplatin Resistance in Epstein-Barr-Virus-Associated Gastric Carcinoma Acquired through ATM Methylation. Cancers (Basel) 2021;13:4252. [PMID: 34503060 DOI: 10.3390/cancers13174252] [Reference Citation Analysis]
8 Liu W, Luo B. The impact of EBV on the epigenetics of gastric carcinoma. Future Virology 2020;15:183-93. [DOI: 10.2217/fvl-2019-0148] [Reference Citation Analysis]
9 Han S, Tay JK, Loh CJL, Chu AJM, Yeong JPS, Lim CM, Toh HC. Epstein–Barr Virus Epithelial Cancers—A Comprehensive Understanding to Drive Novel Therapies. Front Immunol 2021;12:734293. [DOI: 10.3389/fimmu.2021.734293] [Reference Citation Analysis]
10 朱晓芸, 李夏, 李素琴, 于红刚. EBV相关性胃癌研究进展. 世界华人消化杂志 2017; 25(15): 1375-1381 [DOI: 10.11569/wcjd.v25.i15.1375] [Reference Citation Analysis]
11 Saju P, Murata-Kamiya N, Hayashi T, Senda Y, Nagase L, Noda S, Matsusaka K, Funata S, Kunita A, Urabe M, Seto Y, Fukayama M, Kaneda A, Hatakeyama M. Host SHP1 phosphatase antagonizes Helicobacter pylori CagA and can be downregulated by Epstein-Barr virus. Nat Microbiol. 2016;1:16026. [PMID: 27572445 DOI: 10.1038/nmicrobiol.2016.26] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
12 Wang J, Zheng X, Qin Z, Wei L, Lu Y, Peng Q, Gao Y, Zhang X, Zhang X, Li Z, Fu Y, Liu P, Liu C, Yan Q, Xiong W, Li G, Lu J, Ma J. Epstein-Barr virus miR-BART3-3p promotes tumorigenesis by regulating the senescence pathway in gastric cancer. J Biol Chem 2019;294:4854-66. [PMID: 30674552 DOI: 10.1074/jbc.RA118.006853] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
13 Liu X, Meltzer SJ. Gastric Cancer in the Era of Precision Medicine. Cell Mol Gastroenterol Hepatol 2017;3:348-58. [PMID: 28462377 DOI: 10.1016/j.jcmgh.2017.02.003] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 11.4] [Reference Citation Analysis]
14 Cheng N, Hui DY, Liu Y, Zhang NN, Jiang Y, Han J, Li HG, Ding YG, Du H, Chen JN, Shao CK. Is gastric lymphoepithelioma-like carcinoma a special subtype of EBV-associated gastric carcinoma? Gastric Cancer. 2015;18:246-255. [PMID: 24771002 DOI: 10.1007/s10120-014-0376-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
15 Yang L, Wei S, Zhao R, Wu Y, Qiu H, Xiong H. Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studies. Sci Rep 2016;6:28919. [PMID: 27354232 DOI: 10.1038/srep28919] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
16 Zhang NN, Chen JN, Xiao L, Tang F, Zhang ZG, Zhang YW, Feng ZY, Jiang Y, Shao CK. Accumulation Mechanisms of CD4(+)CD25(+)FOXP3(+) Regulatory T Cells in EBV-associated Gastric Carcinoma. Sci Rep. 2015;5:18057. [PMID: 26673957 DOI: 10.1038/srep18057] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
17 Vickers MA, Wilkie GM, Robinson N, Rivera N, Haque T, Crawford DH, Barry J, Fraser N, Turner DM, Robertson V, Dyer P, Flanagan P, Newlands HR, Campbell J, Turner ML. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol 2014;167:402-10. [PMID: 25066775 DOI: 10.1111/bjh.13051] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 9.0] [Reference Citation Analysis]
18 Zhou SJ, Wei J, Su S, Chen FJ, Qiu YD, Liu BR. Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy. J Cancer 2017;8:3689-96. [PMID: 29151956 DOI: 10.7150/jca.19501] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
19 Waldum H, Mjønes P. Towards Understanding of Gastric Cancer Based upon Physiological Role of Gastrin and ECL Cells. Cancers (Basel) 2020;12:E3477. [PMID: 33266504 DOI: 10.3390/cancers12113477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Zeng Y, Jin RU. Molecular Pathogenesis, Targeted Therapies, and Future Perspectives for Gastric Cancer. Semin Cancer Biol 2021:S1044-579X(21)00297-2. [PMID: 34933124 DOI: 10.1016/j.semcancer.2021.12.004] [Reference Citation Analysis]
21 Xu Q, DU J, Liu B. Lymphoepithelioma-like gastric carcinoma located in the lesser curvature of the gastric body: A case report and review of the literature. Mol Clin Oncol 2016;4:405-8. [PMID: 26998292 DOI: 10.3892/mco.2015.717] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Dottermusch M, Krüger S, Behrens HM, Halske C, Röcken C. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study. Virchows Arch 2019;475:563-71. [PMID: 31332522 DOI: 10.1007/s00428-019-02624-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
23 Zubarayev M, Min EK, Son T. Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond. Transl Gastroenterol Hepatol 2019;4:59. [PMID: 31559340 DOI: 10.21037/tgh.2019.08.05] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
24 Bristol JA, Djavadian R, Albright ER, Coleman CB, Ohashi M, Hayes M, Romero-Masters JC, Barlow EA, Farrell PJ, Rochford R, Kalejta RF, Johannsen EC, Kenney SC. A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection. PLoS Pathog 2018;14:e1007179. [PMID: 30052684 DOI: 10.1371/journal.ppat.1007179] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
25 Lung RW, Tong JH, To KF. Emerging roles of small Epstein-Barr virus derived non-coding RNAs in epithelial malignancy. Int J Mol Sci. 2013;14:17378-17409. [PMID: 23979421 DOI: 10.3390/ijms140917378] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
26 Liu X, Liu J, Qiu H, Kong P, Chen S, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Xu D, Sun X. Prognostic significance of Epstein-Barr virus infection in gastric cancer: a meta-analysis. BMC Cancer 2015;15:782. [PMID: 26498209 DOI: 10.1186/s12885-015-1813-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
27 Siddiqi UZ, Vaidya AS, Li X, Marcon E, Tsao SW, Greenblatt J, Frappier L. Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation. J Virol 2019;93:e00989-19. [PMID: 31341047 DOI: 10.1128/JVI.00989-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Liu S, Jin L, Xu X, Lin N, Lei B, Shen H. Pathological and computed tomography findings of lymphoepithelioma-like gastric carcinoma with epithelioid granulomas: A case report. Oncol Lett 2013;5:549-51. [PMID: 23420641 DOI: 10.3892/ol.2012.1070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
29 Böger C, Krüger S, Behrens HM, Bock S, Haag J, Kalthoff H, Röcken C. Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations. Ann Oncol 2017;28:1005-14. [PMID: 28453696 DOI: 10.1093/annonc/mdx047] [Cited by in F6Publishing: 30] [Reference Citation Analysis]
30 Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun 2018;9:1777. [PMID: 29725014 DOI: 10.1038/s41467-018-04179-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 78] [Article Influence: 17.5] [Reference Citation Analysis]
31 Pellino A, Brignola S, Riello E, Niero M, Murgioni S, Guido M, Nappo F, Businello G, Sbaraglia M, Bergamo F, Spolverato G, Pucciarelli S, Merigliano S, Pilati P, Cavallin F, Realdon S, Farinati F, Dei Tos AP, Zagonel V, Lonardi S, Loupakis F, Fassan M. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. J Pers Med 2021;11:1095. [PMID: 34834447 DOI: 10.3390/jpm11111095] [Reference Citation Analysis]